Cargando…
Anti-ROR1 scFv-EndoG as a Novel Anti-Cancer Therapeutic Drug
AIM: Immunotoxins are proteins that consist of an antibody fragment linked to a toxin, used as agents for targeted therapy of cancers. Although the most potent immunotoxins are made from bacterial and plant toxins, obstacles which contribute to poor responses are immunogenicity in patients and rapid...
Autores principales: | Bemani, Peyman, Mohammadi, Mozafar, Hakakian, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844643/ https://www.ncbi.nlm.nih.gov/pubmed/29373898 http://dx.doi.org/10.22034/APJCP.2018.19.1.97 |
Ejemplares similares
-
Crystal structure of the EndoG/EndoGI complex: mechanism of EndoG inhibition
por: Loll, Bernhard, et al.
Publicado: (2009) -
Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC
por: Harrasser, Micaela, et al.
Publicado: (2022) -
Isolation and characterization of human anti-CD20 single-chain variable fragment (scFv) from a Naive human scFv library
por: Shams, Nasir, et al.
Publicado: (2022) -
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
por: Kang, Chung Hyo, et al.
Publicado: (2020) -
scFv Antibody: Principles and Clinical Application
por: Ahmad, Zuhaida Asra, et al.
Publicado: (2012)